Microbiome modification and improvement of signs and symptoms of COVID-19: Ileocolonic-release nicotinamide in a prospective, double-blind, randomized, placebo-controlled trial

Stefan Schreiber,Georg H. Waetzig,Corinna Geisler,Kristina Schlicht, S. Franzenburg, Víctor A. López-Agudelo, Romina di Giuseppe,Daniel Pape,Thomas Bahmer,Michael Krawczak, Elda Kokott, Oliver Harzer, Jennifer R. Kramer, T. von Schrenck,Felix Sommer, Helena U. Zacharias,Jan Heyckendorf,Konrad Aden, Regina Hollweck, Matthias Laudes,Philip Rosenstiel

Zeitschrift Fur Gastroenterologie（2023）

引用 0|浏览4

暂无评分

摘要

Introduction Infection with SARS-CoV-2 leads to pronounced changes in the intestinal microbiome and also decay of tryptophan that are both related to disease severity. Supplementation of tryptophan metabolism using ileocolonic-release nicotinamide may stabilize the microbiome and alleviate COVID-19 symptoms.

查看译文

关键词

microbiome modification,ileocolonic-release,double-blind,placebo-controlled

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要